Roche Holding AG
RO
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Roche Holding AG News & Analysis
stocks
6 undervalued stocks with low beta
Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.
stocks
An undervalued, wide-moat name in healthcare
Companies racing for a coronavirus cure have moved to lofty valuations. Morningstar analyst Alex Morozov is looking for lesser-known healthcare names.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,824.20 | 19.20 | -0.22% |
| CAC 40 | 8,025.80 | 66.13 | 0.83% |
| DAX 40 | 23,464.63 | 225.45 | 0.97% |
| Dow JONES (US) | 46,991.94 | 543.67 | 1.17% |
| FTSE 100 | 9,609.53 | 74.62 | 0.78% |
| HKSE | 25,894.55 | 178.05 | 0.69% |
| NASDAQ | 22,953.46 | 81.46 | 0.36% |
| Nikkei 225 | 48,659.52 | 33.64 | 0.07% |
| NZX 50 Index | 13,480.43 | 19.42 | -0.14% |
| S&P 500 | 6,750.33 | 45.21 | 0.67% |
| S&P/ASX 200 | 8,537.00 | 26.70 | -0.31% |
| SSE Composite Index | 3,870.02 | 33.26 | 0.87% |